Current Report Filing (8-k)
December 18 2018 - 4:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 12, 2018
Achillion Pharmaceuticals, Inc.
(Exact name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-33095
|
|
52-2113479
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
300 George Street
New Haven, CT
|
|
06511
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(203) 624-7000
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act
(17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On December 12, 2018, the Board of Directors of Achillion Pharmaceuticals, Inc. (the
Company) appointed Keri Lantz, on an interim basis, to the positions of principal financial officer and principal accounting officer, effective as of January 1, 2019. This appointment is being made in connection with the departure
of Mary Kay Fenton, the Companys current Chief Financial Officer, whose resignation was previously announced and is effective as of December 28, 2018.
Ms. Lantz, age 44, has served as the Companys Corporate Controller and Vice President of Finance since January 2017. From January 2014 to December
2016, Ms. Lantz served as the Companys Corporate Controller and Executive Director, Financial Reporting and from January 2011 to December 2013 as the Companys Corporate Controller and Senior Director, Financial Reporting. Prior to
joining the Company in January 2007, Ms. Lantz, a certified public accountant, held positions at CUNO, Inc., a manufacturing and technology company which was acquired by 3M Company in 2005, and the accounting firm, Blum Shapiro. Ms. Lantz
holds a Bachelor of Science in accounting from Central Connecticut State University.
Ms. Lantz does not have a family relationship with any of the
Companys officers or directors and has no direct or indirect interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation
S-K.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
ACHILLION PHARMACEUTICALS, INC.
|
|
|
|
|
Date: December 18, 2018
|
|
|
|
By:
|
|
/s/ Mary Kay Fenton
|
|
|
|
|
|
|
Mary Kay Fenton
|
|
|
|
|
|
|
Chief Financial Officer
|
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Apr 2023 to Apr 2024